Skip to main content

Table 3 Predicted kinase inhibitors

From: The use of whole exome sequencing and murine patient derived xenografts as a method of chemosensitivity testing in sarcoma

Patient Diagnosis Database Gene Variant Therapeutic
Pt1 Osteosarcoma NCI match clinical trials KIT E142Q Sunitinib
DSigDB FDA approved kinase inhibitors KIT E142Q Imatinib, Sorafenib, Dasatanib, Sunitinib, Nilotinib, Pazopanib, Axitinib, Cabozantinib
Pt6 Ewing’s sarcoma DSigDB FDA approved kinase inhibitors ALK C928fs Crizotinib, Ceritinib
Pt7 Undifferentiated pleomorphic sarcoma DSigDB FDA approved kinase inhibitors ABL2 I471fs Dasatinib
Pt8 Alveolar rhabdomyosarcoma DSigDB FDA approved kinase inhibitors NTRK1 G18E Imatinib
Pt9 Leiomyosarcoma DSigDB FDA approved kinase inhibitors ALK C928fs, F921L Crizotinib, Ceritinib
Pt12 Undifferentiated pleomorphic sarcoma DSigDB FDA approved kinase inhibitors JAK2 S593F Ruxolitinib